

Whereas, I/we Kenji MIYAMOTO, Yousuke YASUDA and Keiji YOSHIOKA,  
all of Tokyo, Japan

hereinafter called assignor(s), have invented certain improvements in

HYALURONIC ACID DERIVATIVE AND DRUG CONTAINING THE SAME

and executed an application for Letters Patent of the United States of America therefor on

September 7, 2006 ; and

Whereas, **SEIKAGAKU CORPORATION** of  
6-1, Marunouchi 1-chome, Chiyoda-ku, Tokyo 100-0005 JAPAN

(assignee), desires to acquire the entire right, title and interest in the application and invention, and to  
any United States patents to be obtained therefor;

Now therefore, for valuable consideration, receipt whereof is hereby acknowledged,

I/We, the above named assignor(s), hereby sell, assign and transfer to the above named  
assignee, its successors and assigns, the entire right, title and interest in the application and the  
invention disclosed therein for the United States of America, including the right to claim priority under  
35 U.S.C. § 119, and I/we request the Director – U.S. Patent and Trademark Office to issue any  
Letters Patent granted upon the invention set forth in the application to the assignee, its successors  
and assigns; and I/we will execute without further consideration all papers deemed necessary by the  
assignee in connection with the United States application when called upon to do so by the assignee.

I/We hereby authorize and request my/our attorneys SUGHRUE MION, PLLC of 2100  
Pennsylvania Avenue, N.W., Washington, D.C. 20037-3213 to insert here in parentheses  
(Application number \_\_\_\_\_, filed \_\_\_\_\_) the filing date and  
application number of said application when known.

Date: September 7, 2006 s/ Kenji Miyamoto

Date: September 7, 2006 s/ Yousuke Yasuda

Date: September 7, 2006 s/ Keiji Yoshiooka

Date: s/ \_\_\_\_\_

Date: s/ \_\_\_\_\_

(Legalization not required for recording but is prima facie evidence of execution under 35 U.S.C. §261)